Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients Peter GhijbenDennis PetrieEmily Lancsar Practical Application 09 April 2021 Pages: 741 - 756
Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies Huajie JinStewart RobinsonSarah Byford Review Article 20 May 2021 Pages: 757 - 770
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine Heleen VellekoopSimone Huygensthe HEcoPerMed Consortium Systematic Review Open access 16 April 2021 Pages: 771 - 788
Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review Jalal DahhamRana RizkMickaël Hiligsmann Systematic Review Open access 06 May 2021 Pages: 789 - 807
What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study Jakob MantheySyed Ahmed HassanJürgen Rehm Systematic Review Open access 10 May 2021 Pages: 809 - 822
Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest Stephanie HarvardGregory R. Werker Original Research Article Open access 07 May 2021 Pages: 823 - 833
Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference Group Chantelle MurleyPetter TinghögKorinna Karampampa Original Research Article Open access 10 May 2021 Pages: 835 - 851
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective Daniel StellatoMarroon E. ThabaneThomas E. Delea Original Research Article 18 May 2021 Pages: 853 - 867